Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insmed (INSM) Common Equity (2016 - 2026)

Insmed's Common Equity history spans 17 years, with the latest figure at $704.9 million for Q1 2026.

  • Quarterly Common Equity rose 610.83% to $704.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $704.9 million through Mar 2026, up 610.83% year-over-year, with the annual reading at $739.0 million for FY2025, 158.95% up from the prior year.
  • Common Equity came in at $704.9 million for Q1 2026, down from $739.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.2 billion in Q2 2025 to a low of -$464.8 million in Q1 2024.
  • The 5-year median for Common Equity is $88.0 million (2022), against an average of $204.8 million.
  • Year-over-year, Common Equity plummeted 940.93% in 2024 and then surged 3119.47% in 2025.
  • Insmed's Common Equity stood at $88.0 million in 2022, then tumbled by 477.4% to -$331.9 million in 2023, then skyrocketed by 185.98% to $285.4 million in 2024, then skyrocketed by 158.95% to $739.0 million in 2025, then decreased by 4.62% to $704.9 million in 2026.
  • Per Business Quant, the three most recent readings for INSM's Common Equity are $704.9 million (Q1 2026), $739.0 million (Q4 2025), and $945.6 million (Q3 2025).